Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713745 | 0.87 | MMP13 (0.47) | ALDH1A1TSHRMMP13EPHX2KMT2A | |
| SCHEMBL2713826 | 0.83 | MMP13 (0.52) | TSHRMMP13CYP1A2CYP2C19KMT2A | |
| SCHEMBL2717547 | 0.81 | EPHX2 (0.46) | MMP13RAF1EPHX2PHGDHCYP1A2 | |
| SCHEMBL18266476 | 0.79 | MMP13 (0.42) | ALDH1A1TSHRMMP13EPHX2KMT2A | |
| SCHEMBL2714620 | 0.79 | SCN9A (0.44) | EPHX2 | |
| SCHEMBL27913797 | 0.79 | MMP13 (0.59) | ALDH1A1MMP13RAF1CYP1A2CYP2C9 | |
| SCHEMBL2716984 | 0.78 | MAPK14 (0.52) | MMP13EPHX2 | |
| SCHEMBL2718865 | 0.78 | MMP13 (0.56) | TSHRMMP13EPHX2KMT2AP2RX7 | |
| SCHEMBL2718670 | 0.77 | EPHX2 (0.50) | TSHRMMP13EPHX2KMT2AP2RX7 | |
| SCHEMBL18266682 | 0.77 | RIPK1 (0.44) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | ALDH1A1 1358/4885TSHR 574/4885MMP13 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.